This is a promotional workshop series, initiated, funded and reviewed by Viatris.
Products and brands will be mentioned. This workshop is intended for UK healthcare professionals.

You have been selected and invited to join one of our free-to-attend, interactive MyWay Menopause & HRT Workshops following your attendance at three or more of our recent, successful MyWay webinars.

Monday 20th June 2022
6.50–9.15pm

Tuesday 5th July 2022
6.50–9.15pm

Thursday 7th July 2022
6.50–9.15pm

Tuesday 12th July 2022
6.50–9.15pm

These interactive workshops will follow the format of Think menopause, Treat menopause and Review menopause. They will include in-depth discussion sessions with Dr Anne Connolly MBE, including top tips and tricks and case-based discussion to help support you to put evidence into practice.

The workshops will also focus on treating the menopause with hormone replacement therapy (HRT) and how to decide which HRT may be appropriate, including the choice of progestogen as part of combined HRT.

You will have the opportunity to ask questions along with peer discussions on current best practice and the challenges you face, in relation to the menopause, in your practice on a day-to-day basis.

Following this engaging workshop, you will increase your knowledge of:
  • The current best practices in menopause management
  • The Government’s Women’s Health Strategy
  • Identifying the right HRT for the right patient at the right time
  • Patient medication reviews, adherence
  • Clinical case studies
  • Patient and HCP challenges in menopause care
This is a promotional workshop series, initiated, funded and reviewed by Viatris.
Products and brands will be mentioned. This workshop is intended for UK healthcare professionals.

Please continue to report suspected adverse drug reactions with any medicine or vaccine to the MHRA through the Yellow Card Scheme. It is easiest and quickest to report adverse drug reactions online via the Yellow Card website: https://yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in the Google Play or Apple App Store. Alternatively, you can report via some clinical IT systems (EMIS/SystemOne/Vision/MiDatabank) or by calling the Commission on Human Medicines (CHM) free phone line: 0800-731-6789. Adverse reactions/events should also be reported to MAH at e-mail address: pv.uk@viatris.com

Click here to access prescribing information for Femoston® (estradiol/dydrogesterone) and Femoston®-conti (estradiol/dydrogesterone)

Femoston® is indicated for estrogen deficiency symptoms in postmenopausal women at least 6 months since last menses and Femoston®-conti is indicated for estrogen deficiency symptoms in postmenopausal women at least 12 months since last menses.

www.mywayhub.co.uk

Treatment Navigator · Stock Availability · Experts Corner

Website contains promotional content

Job code: FEM-2022-0031
May 2022